The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes
Open accessAbstract
Recently, a number of studies have demonstrated the potential beneficial role for novel anti-diabetic GLP-1 receptor agonists (GLP-1RAs) in the skeleton metabolism in diabetic rodents and patients. In this study, we evaluated the impacts of the synthetic GLP-1RA Liraglutide on bone mass and quality in osteoporotic rats induced by ovariectomy (OVX) but without diabetes, as well as its effect on the adipogenic and osteoblastogenic differentiation of bone marrow stromal cells (BMSCs). Three months after sham surgery or bilateral OVX, eighteen 5-month old female Wistar rats were randomly divided into three groups to receive the following treatments for 2 months: (1) Sham + normal saline; (2) OVX + normal saline; and (3) OVX + Liraglutide (0.6 mg/day). As revealed by micro-CT analysis, Liraglutide improved trabecular volume, thickness and number, increased BMD, and reduced trabecular spacing in the femurs in OVX rats; similar results were observed in the lumbar vertebrae of OVX rats treated with Liraglutide. Following in vitro treatment of rat and human BMSCs with 10 nM Liraglutide, there was a significant increase in the mRNA expression of osteoblast-specific transcriptional factor Runx2 and the osteoblast markers alkaline phosphatase (ALP) and collagen α1 (Col-1), but a significant decrease in peroxisome proliferator-activated receptor γ (PPARγ). In conclusion, our results indicate that the anti-diabetic drug Liraglutide can exert a bone protective effect even in non-diabetic osteoporotic OVX rats. This protective effect is likely attributable to the impact of Liraglutide on the lineage fate determination of BMSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Animal models have indicated positive effects of the GLP-1 receptor agonists exendin-4 and liraglutide on bone metabolism.
“Animal models have indicated positive effects of the GLP-1 receptor agonists exendin-4 and liraglutide on bone metabolism (11–13).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
Bouxsein, M., Boyd, S. K., Christiansen, B., Guldberg, R. E., Jepsen, K. J., & Müller, R. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.141 · Cited by 4,461
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244
Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro
Jaiswal, N., Haynesworth, S. E., Caplan, A. I., & Bruder, S. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199702)64:2 · Cited by 2,557
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 871
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419900 · Cited by 730
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“In rodent models, Liraglutide can stimulate calcitonin release, which can bind to receptors on rat osteoclasts and inhibit bone resorption [35, 41].”
BackgroundCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 532
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S. C., Svaldi, M., & Rizzoli, V. (2005) · Blood · doi:10.1182/blood-2004-12-4986 · Cited by 322
The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 293
Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors1
Bollag, R. J., Zhong, Q. P. W., Phillips, P., Min, L., Zhong, L., Cameron, R. S., Mulloy, A. L., Rasmussen, H., Qin, F., Ding, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7366 · Cited by 265
Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang‐Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 259
Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies
Molinuevo, M. S., Schurman, L., McCarthy, A. D., Cortizo, A. M., Tolosa, M. J., Gangoiti, M. V., Arnol, V., & Sedlinsky, C. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090732 · Cited by 236
Su, B., Sheng, H., Zhang, M., Bu, L., Yang, P., Li, L., Li, F. Y., Sheng, C., Han, Y., Qu, S., et al. (2014) · Endocrine · doi:10.1007/s12020-014-0361-4 · Cited by 203
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 197
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Nuche‐Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro‐Mora, J. J., & Villanueva‐Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192
Receptors and effects of gut hormones in three osteoblastic cell lines
Pacheco-Pantoja, E. L., Ranganath, L. R., Gallagher, J. A., Wilson, P. J., & Fraser, W. D. (2011) · BMC Physiology · doi:10.1186/1472-6793-11-12 · Cited by 175
High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis
Wittrant, Y., Gorin, Y. C., Woodruff, K., Horn, D., Abboud, H. E., Mohan, S., & Abboud‐Werner, S. L. (2008) · Bone · doi:10.1016/j.bone.2008.02.006 · Cited by 169
Nuche‐Berenguer, B., Portal‐Núñez, S., Moreno, P., González, N., Acitores, A., López‐Herradón, A., Esbrit, P., Valverde, I., & Villanueva‐Peñacarrillo, M. L. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22243 · Cited by 146
Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
Nuche‐Berenguer, B., Moreno, P., Portal‐Núñez, S., Dapía, S., Esbrit, P., & Villanueva‐Peñacarrillo, M. L. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.06.010 · Cited by 144
Sanz, C., Vázquez, P., Blázquez, C. P., Barrio, P. A., Álvarez, M., & Blázquez, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2009 · Cited by 138
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 138
Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
Schwartz, A. V., Margolis, K. L., Sellmeyer, D. E., Vittinghoff, E., Ambrosius, W. T., Bonds, D. E., Josse, R. G., Schnall, A. M., Simmons, D. L., Hue, T. F., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2184 · Cited by 131
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 128
New factors controlling the balance between osteoblastogenesis and adipogenesis
Abdallah, B. M., & Kassem, M. S. (2011) · Bone · doi:10.1016/j.bone.2011.06.030 · Cited by 124
Taipaleenmäki, H., Abdallah, B. M., Aldahmash, A. M., Säämänen, A., & Kassem, M. S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.12.015 · Cited by 116
Wu, J. Y., Aarnisalo, P., Bastepe, M., Sinha, P. S., Fulzele, K. S., Selig, M. K., Chen, M., Poulton, I. J., Purton, L. E., Sims, N. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46406 · Cited by 106
Mabilleau, G., Mieczkowska, A., Irwin, N., Flatt, P. R., & Chappard, D. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0146 · Cited by 106
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0015 · Cited by 96
Dienelt, A., & Nieden, N. I. Z. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0205 · Cited by 91
Tang, Z., Xie, Y., Yang, F., Huang, Y., Wang, C., Dai, K., Zheng, X., & Zhang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066263 · Cited by 85
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
AOYAMA, E., Watari, I., Podyma‐Inoue, K. A., Yanagishita, M., & Ono, T. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1787 · Cited by 52
Mieczkowska, A., Mansur, S., Bouvard, B., Flatt, P. R., Thorens, B., Irwin, N., Chappard, D., & Mabilleau, G. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2845-8 · Cited by 47
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
Ellenbroek, J. H., Töns, H. A. M., Westerouen van Meeteren, M. J. A., de Graaf, N., Hanegraaf, M. A., Rabelink, T. J., Carlotti, F., & de Koning, E. J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2957-2 · Cited by 43
Ko, C., Siu, W. S., Wong, H., Shum, W., Fung, K., Lau, C. B., & Leung, P. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf202015t · Cited by 32
Bone: Incretin Hormones Perceiver or Receiver?
Dicembrini, I., Mannucci, E., & Rotella, C. M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/519784 · Cited by 30
Papazafiropoulou, A. K., Παπάνας, Ν., Pappas, S. I., & Maltezos, E. S. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140217114848 · Cited by 7
Flagged first, then by citations
Cited by
Sorted by citations
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Picke, A., Campbell, G. M., Napoli, N., Hofbauer, L. C., & Rauner, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0456 · Cited by 207
BMI and BMD: the potential interplay between obesity and bone fragility
Palermo, A., Tuccinardi, D., Defeudis, G., Watanabe, M., D’Onofrio, L., Lauria Pantano, A., Napoli, N., Pozzilli, P., & Manfrini, S. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060544 · Cited by 197
Savvidis, C., Tournis, S., & Dede, A. D. (2018) · HORMONES · doi:10.1007/s42000-018-0018-4 · Cited by 155
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125
The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00098 · Cited by 124
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
Schiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 110
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I. R., & Thrailkill, K. M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 103
Wu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92
de Mesquita, F. C., Guixé‐Muntet, S., Fernández‐Iglesias, A., Maeso‐Díaz, R., Vila, S., Hide, D., Ortega‐Ribera, M., Rosa, J. L., García‐Pagán, J. C., Bosch, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02866-y · Cited by 78
Hygum, K., Harsløf, T., Jørgensen, N. R., Rungby, J., Pedersen, S. B., & Langdahl, B. L. (2019) · Bone · doi:10.1016/j.bone.2019.115197 · Cited by 77
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 74
Saulīte, L., Jēkabsons, K., Kļaviņš, M., Muceniece, R., & Riekstiņa, U. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.029 · Cited by 73
Casimiro, I., Sam, S., & Brady, M. (2019) · Physiological Reports · doi:10.14814/phy2.14111 · Cited by 72
Xie, B., Chen, S., Xu, Y., Han, W., Hu, R., Chen, M., Zhang, Y., & Ding, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.697442 · Cited by 72
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 68
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
Mabilleau, G., Pereira, M., & Chenu, C. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0278 · Cited by 66
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Adiponectin signaling and its role in bone metabolism
Pal China, S., Sanyal, S., & Chattopadhyay, N. (2018) · Cytokine · doi:10.1016/j.cyto.2018.06.012 · Cited by 53
Glucose Metabolism in Osteoblasts in Healthy and Pathophysiological Conditions
Donat, A., Knapstein, P.-R., Jiang, S., Baranowsky, A., Ballhause, T.-M., Frosch, K.-H., & Keller, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084120 · Cited by 53
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
Living probiotic biomaterials for osteoporosis therapy
Chen, Z., Cai, Z., Zhuang, P., Li, F., Cui, W., & Li, Z. (2022) · Biomedical Technology · doi:10.1016/j.bmt.2022.11.007 · Cited by 49
Wen, B., Zhao, L., Zhao, H., & Wang, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6043 · Cited by 46
Self-citationThe osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Pal, S., Maurya, S. K., Chattopadhyay, S., China, S. P., Porwal, K., Kulkarni, C., Sanyal, S., Sinha, R. A., & Chattopadhyay, N. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.024 · Cited by 46
Eftekhari, S., Montazeri, H., & Tarighi, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173102 · Cited by 46
Wang, N., Gao, J., Jia, M., Ma, X., Lei, Z., Da, F., Yan, F., Zhang, H., Zhou, Y., Li, M., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485776 · Cited by 42
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 42
Relationships between Bone Turnover and Energy Metabolism
Fernandes, T., Gonçalves, L. M. L., & Brito, J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/9021314 · Cited by 42
Pang, Y., Yuan, X., Guo, J., Wang, X., Yang, M., Zhu, J., & Wang, J. (2018) · Journal of Periodontal Research · doi:10.1111/jre.12607 · Cited by 39
Self-citationMansur, S. A., Mieczkowska, A., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00051 · Cited by 39
Structure and Function of Bone Marrow Adipocytes
de Paula, F. J. A., & Rosen, C. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c170010 · Cited by 39
Li, J., Fu, L.-Z., Liu, L., Xie, F., & Dai, R.-C. (2017) · Medical Science Monitor · doi:10.12659/msm.906603 · Cited by 38
Glorie, L., D’Haese, P. C., & Verhulst, A. (2016) · Bone · doi:10.1016/j.bone.2016.08.009 · Cited by 37
Jing, M., Sun, J., Wu, J., & Zheng, X. (2019) · Europe PMC (PubMed Central) · Cited by 37
Hansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 37
Guo, Z., Chen, R., Zhang, F., Ding, M. L., & Wang, P. (2018) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2018.03.014 · Cited by 36
Review article: effects of type 2 diabetes therapies on bone metabolism
Vianna, A. G. D., Sanches, C. P., & Barreto, F. C. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0274-5 · Cited by 36
A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
Nissen, A. A., Marstrand, S. D., Skov‐Jeppesen, K., Bremholm, L., Hornum, M., Andersen, U. B., Holst, J. J., ROSENKILDE, M. M., & Hartmann, B. (2019) · JBMR Plus · doi:10.1002/jbm4.10209 · Cited by 36
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 35
Wu, X., Li, S., Xue, P., & Li, Y. (2018) · PubMed Central · doi:10.14348/molcells.2018.2340 · Cited by 34
Zhang, Y., Yuan, X., Wu, Y., Pei, M., Yang, M., Wu, X., Pang, Y., & Wang, J. (2020) · Journal of Dentistry · doi:10.1016/j.jdent.2020.103310 · Cited by 33
Gao, L., Li, S., & Li, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4397 · Cited by 33
Iron metabolism and ferroptosis in diabetic bone loss: from mechanism to therapy
Bao, J., Yan, Y., Zuo, D., Zhuo, Z., Sun, T., Lin, H., Han, Z., Zhao, Z., & Yu, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1178573 · Cited by 33
Alliances of the gut and bone axis
Hansen, M. S., & Frost, M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.06.024 · Cited by 32
Agrawal, V., Amasa, S., Karabacak, M., & Margetis, K. D. (2024) · Neurosurgery · doi:10.1227/neu.0000000000003291 · Cited by 27
Eriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00781 · Cited by 26
Kim, H., Choi, S., Gu, M., Ko, S., Kwon, J.-H., Han, J., Kim, J. H., & Kim, M. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3843 · Cited by 26
Gut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 26
Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
Lv, F., Cai, X., Lin, C., Yang, W., & Ji, L. (2024) · Pharmaceuticals · doi:10.3390/ph17121655 · Cited by 25
Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health
Egger, A., KRAENZLIN, M. E., & Meier, C. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0337-9 · Cited by 25
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 23
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 23
Vasto, S., Amato, A., Proia, P., & Baldassano, S. (2022) · Biology · doi:10.3390/biology11020296 · Cited by 22
Sedky, A. A. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12664 · Cited by 22
Kang, I. S., Agidigbi, T. S., Kwon, Y. M., Kim, D.-G., Kim, R. I., In, G., Lee, M. H., & Kim, C. (2020) · Nutrients · doi:10.3390/nu12082415 · Cited by 21
The decline of whole-body glucose metabolism in ovariectomized rats
Wen, M., Fang, P., Huang, G., Shi, M., & Zhang, Z. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.09.027 · Cited by 21
Effect of type 2 diabetes medications on fracture risk
Guja, C., Guja, L., & Miulescu, R. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.51 · Cited by 20
Charoenphandhu, N., Suntornsaratoon, P., Sa‐nguanmoo, P., Tanajak, P., Teerapornpuntakit, J., Aeimlapa, R., Chattipakorn, N., & Chattipakorn, S. C. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.01.006 · Cited by 20
Wu, Z., Deng, W., Ye, Y., Xu, J., Han, D., Zheng, Y., & Zheng, Q. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1378291 · Cited by 19
Incretin-based therapy for the treatment of bone fragility in diabetes mellitus
Mabilleau, G., Gobron, B., Bouvard, B., & Chappard, D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.008 · Cited by 19
The effects of anti‐obesity medications on bone metabolism: A critical appraisal
Anastasilakis, A. D., Paccou, J., Palermo, A., & Pοlyzos, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16541 · Cited by 18
Effects of weight-loss interventions on bone health in people living with obesity
Paccou, J., Gagnon, C., Yu, E. W.-Y., & Rosen, C. J. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf135 · Cited by 18
Management of fracture risk in patients with diabetes—Chinese Expert Consensus
Liu, J., Zhu, D., Mu, Y., & Xia, W. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12962 · Cited by 18
Self-citationYang, M., Pang, Y., Pei, M., Li, Y., Yuan, X., Tang, R., & Wang, J. (2022) · Journal of Diabetes Research · doi:10.1155/2022/8260111 · Cited by 17
Interplay between bone and incretin hormones: A review
Mabilleau, G. (2016) · Morphologie · doi:10.1016/j.morpho.2016.06.004 · Cited by 16
Pereira, D. E., Tummala, S., Mittal, M. M., Obey, M. R., Berkes, M. B., McAndrew, C. M., & Wilson, J. L. (2025) · Injury · doi:10.1016/j.injury.2025.112746 · Cited by 15
Progress in anti-ageing drug research for age-related diseases: A review
Zhou, Z., Duan, H.-T., Xue, S.-T., & Li, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102982 · Cited by 11
Fathy, M. A., Anbaig, A., Aljafil, R., El-sayed, S. F., Abdelnour, H. M., Ahmed, M. M., Abdelghany, E. M. A., Alnasser, S. M., Hassan, S. M. A., & Shalaby, A. M. (2023) · Microscopy and Microanalysis · doi:10.1093/micmic/ozad102 · Cited by 10
Zhou, W., Huang, W., Shen, X., Huang, K., Tian, R., Yuan, Y., & Deng, J. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10648-3 · Cited by 9
Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes
Dalsgaard, N. B., Gasbjerg, L. S., Helsted, M. M., Hansen, L. S., Hansen, N. L., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023) · Bone · doi:10.1016/j.bone.2023.116687 · Cited by 9
Younan, N., Elattar, S., Youssef, M. F., Rashed, L. A., & Estaphan, S. (2019) · Physiological Reports · doi:10.14814/phy2.14191 · Cited by 9
A quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Zhou, Y. J., Xue, X., Guo, Y., Liu, H., Hou, Z., Zhou, C., Wang, N., Li, F., & Wang, Y. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211032133 · Cited by 8
Guo, H., Sui, C., Ge, S., Cai, J. Q., Lin, D., Guo, Y., Wang, N., Zhou, Y., Ying, R., Zha, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3550 · Cited by 8
Zheng, M., Zhao, J., Wang, Y., Cui, Z., Qiao, Z., Wu, H., Shi, C., & Wang, X. (2025) · Medicine · doi:10.1097/md.0000000000043239 · Cited by 7
Self-citationLipopeptides as Therapeutics: Applications and In Vivo Quantitative Analysis
Zemenová, J., Sýkora, D., Maletı́nská, L., & Kuneš, J. (2016) · Bioanalysis · doi:10.4155/bio-2016-0206 · Cited by 7
Association between low C-peptide and fragility fractures in postmenopausal women without diabetes
Ferro, Y., Russo, C., Russo, D., Gazzaruso, C., Coppola, A., Gallotti, P., Zambianchi, V., Fodaro, M., Romeo, S., Galliera, E., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0672-4 · Cited by 7
Mermet, M., Denom, J., Mieczkowska, A., Wery, M., Biggs, E. K., Gribble, F. M., Reimann, F. M., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00086.2025 · Cited by 5
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 5
Chang, Y. K., Chi, K.-Y., Song, J., Chen, C., & Lin, H.-M. (2025) · Global Spine Journal · doi:10.1177/21925682251383170 · Cited by 5
Liu, H., Tian, F., Hu, Y., Ping, S.-H., & Zhang, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s404392 · Cited by 4
Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats
Rossetti, C. L., Andrade, I. S., Boa, L. F. F., Neves, M. B., Fassarella, L. B., Bertasso, I. M., de Souza, M. D. G. C., Bouskela, E., Lisboa, P. C., Takyia, C. M., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112374 · Cited by 3
Emerging incretin hormones actions: focus on bone metabolism
Grammatiki, M., Antonopoulou, V., & Kotsa, K. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03008-6 · Cited by 3
Almohammad, A. A., Aldossari, S. K., Sukumbaji, Z. A., Faden, R. A., Almutairi, M. A., Al-Harbi, N. H., Al-Saaib, M. Y., Almarshedy, B., Alharabi, E., Alhazri, W. A., et al. (2025) · Cureus · doi:10.7759/cureus.95792 · Cited by 2
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 1
Conte, C., Bouillon, R., & Napoli, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00040-3 · Cited by 1
Ковальчук, А., Зінич, О., Prybyla, О. В., Кushnareva, N. M., Ковальчук, В. М., & Shyshkan-Shyshova, К. О. (2022) · World Science · doi:10.31435/rsglobal_ws/30042022/7803 · Cited by 1
Тимкина, Н. В., Semenova, N. Y., Симаненкова, А. В., Zinserling, V. A., Vlasov, T. D., Bairamov, A. A., Константиновна, Х. А., Shimshilashvili, A., Тимофеева, В. А., & Каронова, Т. Л. (2023) · Diabetes Mellitus · doi:10.14341/dm12967 · Cited by 1
Bone remodeling in experimental diabetes mellitus and surgical menopause in Wistar rats
Тимкина, Н. В., Симаненкова, А. В., Bairamov, A. A., Kokina, M. A., Semenova, N. Y., Gagiev, А. Z., Каронова, Т. Л., & Grineva, E. N. (2023) · Obesity and metabolism · doi:10.14341/omet12961 · Cited by 1
Kasotas, A., & Apostolopoulou, M. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2652305 · Cited by 1
Response to the Letter by Napoli N., et al
Iepsen, E. W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3142
Einfluss oraler Antidiabetika auf Knochenstoffwechsel und Frakturrisiko
Traechslin, C., Vavanikunnel, J., KRAENZLIN, M. E., & Meier, C. (2018) · Osteologie/Osteology · doi:10.1055/s-0038-1636976
Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030
Self-citationRISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
NURULLINA, G. M., Илгисовна, А. Г., Krasnoperova, O. V., Alekseeva, M. M., ALEKSANDROVA, O. V., & CHERNOVA, A. V. (2018) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2018-25-4-115-123
Zhang, Q., Zhang, X., & Niu, C.-Y. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i11.393
A Study of the Treatment of Osteoporosis in Type 2 Diabetes Mellitus
郑, 靖. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1472035
A cross-sectional study on the symptoms of depression in dental students in Kerbela
Abass, A. A., Alhashem, R., & Alhashem, G. (2024) · Technium BioChemMed · doi:10.47577/biochemmed.v11i.12117
Modulation of Bone Turnover Markers with Dipeptidyl Deptidase-4: Interplay in Bone Health
Ahmed, F., Ahmad, S. S., Najmi, A. K., & Khan, M. A. (2025) · Current Drug Therapy · doi:10.2174/0115748855339134250115052747
Zavrak, N., Alpan, A. L., & Özmen, Ö. (2026) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2026.106519
Bojanowski, H. T., Marczak, Z., Sito, M., Jurkowski, F., Wójcik, Ł., Gawron, N., Dobracka, A., Zachar, K., Jarowicz, M., & Czmyr, J. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.90.70093
Metadata
- Authors
- Lu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., Sun, L., Zhao, H., Tao, B., & Liu, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Tao, Bei
- Liu, Jianmin
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-15
- Volume
- 10
- Issue
- 7
- Pages
- e0132744
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4503456
- OpenAlex
- W897329354
- Cited by
- 108
- References
- 42
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 8 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 14 · 2018: 18 · 2017: 12 · 2016: 6 · 2015: 1
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81370977, 81170804, 81370018)
- Shanghai Municipal Health Bureau
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, GLP-1 receptor agonists, osteoporosis, ovariectomy, bone mass, bone quality, mesenchymal stem cells, osteogenic differentiation, adipogenesis, Runx2, PPARγ, trabecular bone
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Bone and Bones, Cells, Cultured, Diabetes Mellitus, Female, Humans, Male, Osteoblasts, Osteogenesis, Osteoporosis, Ovariectomy, Bone Density, Rats, Wistar, Anabolic Agents, PPAR gamma, Adipogenesis, Rats, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
